Blackstone Life Sciences to cover $1.5 billion of Pfizer's berobenatide costs

Blackstone Life Sciences will bear $1.5 billion of the development costs of Pfizer's berobenatide through 2028, according to details published on November 12, 2026. The investor will receive payments linked to milestones.

What happened

The agreement links a large pharmaceutical group with a private equity investor active in life sciences. Blackstone Life Sciences takes on the cost of developing berobenatide, a weight-loss drug designed to be taken once a month. The commitment totals $1.5 billion and covers the period through 2028.

In return, Blackstone Life Sciences is entitled to payments that depend on milestones. The details do not specify which milestones apply or how large each payment would be.

Why it matters

The structure splits the cost of drug development between two parties. Blackstone Life Sciences supplies the capital. Pfizer, as the company behind berobenatide, has its development costs for the program funded through 2028. The investor's return depends on milestones, so it is linked to progress of the drug rather than to a fixed schedule.

The scale and the time frame are clear: $1.5 billion over a period ending in 2028. Other terms of the arrangement, including the counterparties' exact rights, have not been described.

Once-monthly dosing is the feature that defines this weight-loss candidate. A funding partner that pays for development in exchange for milestone-based payments places part of the program's financing outside the pharmaceutical group.

For investors, the deal is a data point on how a pharmaceutical group and a private capital provider can structure the funding of a single drug program. No information has been given on the financial effect for either party.

What to watch next

The funding window runs through 2028, so development spending under the agreement will be incurred over the coming years. The milestones that trigger payments to Blackstone Life Sciences are the central variable of the arrangement, and they have not been detailed.

Further information from the two companies on the terms would clarify the structure, including how milestones are defined and how payments are scheduled. No market data on Pfizer shares is available for this report, so the reaction of the stock is not covered.